Friday, February 20, 2009

Gefitinib

Oral gefitinib was effective for the treatment of locally advanced and metastatic non–small cell lung cancer.

read more http://www.hemonctoday.com/article.aspx?rid=33090

stage III non–small-cell lung cancer.

a plateau in survival using current chemotherapy agents cisplatin, etoposide and radiation against stage III NSCLC reached.

read more at http://www.hemonctoday.com/article.aspx?rid=33196

Clinical News on Lung Cancer

Read http://www.hemonctoday.com/Home.aspx?specialty=Lung%20Cancer

Sunday, February 1, 2009

Lung Pathology

see chapter 22 of The Practice of Surgical Pathology By Diana Weedman Molavi (A Beginer's Guide to Diagnotic Practic published by Springer) preview (chapter 22 not in preview) available at http://books.google.com/books?id=iXZ1AVTwhM0C&pg=PA102&lpg=PA102&dq=pleomorphic+nuclei&source=web&ots=eJtCqG_awN&sig=2ePazeBV8vkRBLOZWu0fejBaX8A&hl=en&sa=X&oi=book_result&resnum=10&ct=result#PPA105,M1

Malignant epithelial cells in primary human lung carcinomas

Malignant epithelial cells in primary human lung carcinomas
read more at http://www.pnas.org/content/89/9/3942.abstract

three genes linked to malignant epithelial cells growth: Scrib, Lgl, Dlg

read more at http://www.hhmi.org/news/perrimon.html

Friday, January 16, 2009

The Biology of Cancer and Aging

People 65 years or older are 10 times more likely to develop cancer than younger people, and the mortality rate for older cancer patients is 16 times greater than the rate for those under 65.

read more in http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/429.

Guided radiation on cancer cells

Image Guided Radiotherapy
(IGRT), can now pin-point the exact location of cancer and direct radiation towards it, improving survival rates.

IGRT prolong life and improve its quality.

read more at http://timesofindia.indiatimes.com/Health__Science/Guided_radiation_to_target_cancer_cells/articleshow/3991030.cms

Radiation to the Head May Prevent Metastases in Small Cell Lung Cancer

Small cell lung cancer makes up about 20 percent of all lung cancers, and is more aggressive than non-small cell lung cancer with fewer treatment options. Most SCLC patients are diagnosed after the cancer has spread outside the lung, and commonly develop brain metastases within two years of diagnosis. With the goal of reducing the risk of brain metastases in small cell lung cancer, an international randomized study of 286 advanced SCLC patients tested the impact of prophylactic cranial irradiation (PCI) in patients who responded to chemotherapy. At one year, only 14.6 percent of patients treated with PCI had symptoms of brain metastases compared with 40.4 percent of patients in the control group. Overall survival doubled in the PCI group, with 27.1 percent of patients still alive after one year compared with 13.3 percent in patients who didn’t receive PCI. Side effects of PCI include headache, nausea and vomiting, and fatigue. Additional data will be presented later this year, but researchers say PCI should become standard practice for SCLC patients with extensive disease. —Elizabeth Whittington.

extracted from: http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/868